Jodi M. Carter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jodi M. Carter has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Amy C. Degnim
Department of Surgery, Mayo Clinic, Rochester, USA
27 shared publications - Tanya L. Hoskin
Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN
26 shared publications - Tina J. Hieken
Mayo Clinic, Rochester, MN
23 shared publications - Sarah Schrup
Mayo Clinic Alix School of Medicine, Mayo Clinic , Rochester, MN 55905
22 shared publications - Aparna Vijayasekaran
Division of Plastic and Reconstructive Surgery Mayo Clinic Rochester Minnesota USA
21 shared publications - Brittany L. Siontis
Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
21 shared publications
Latest Publications
- 21 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1093-1105
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
- 21 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1093-1105
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Purpose:To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment.Experimental Design:With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins.Results:A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing.Conclusions:Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Purpose:To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment.Experimental Design:With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins.Results:A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P < 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing.Conclusions:Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 3. Kaplan Meier survival curve of distant recurrence free survival (DRFS).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 1. Clinical response in one representative patient treated with trimodality therapy who experienced a pathologic complete response to preoperative chemoradiation; a) baseline photograph at time of diagnosis/ Pre-treatment, b) photograph after induction chemotherapy, c) photograph after completion of chemoradiation, prior to surgery.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Supplemental Figure 2. Kaplan Meier survival curve of local recurrence free survival (LRFS).